Data from the LOXO-TRK-14001, SCOUT, and NAVIGATE trials support the full approval of larotrectinib in NTRK gene fusion-positive tumors.
Approval Alert | Larotrectinib in Adult and Pediatric NTRK+ Solid Tumors
Advertisement
Advertisement
- News
- Media
- Conferences
- Publications
- Events
- CME/CE
- Resources
- Career Center
- Subscribe
- Adverse Effects
- Brain Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Genitourinary Cancers
- Gynecologic Cancers
- Head & Neck Cancer
- Hematologic Oncology
- Infection
- Leukemia
- Lung Cancer
- Lymphoma
- Neuroendocrine Tumors
- Oncology
- Pediatric Cancers
- Radiation Oncology
- Sarcoma
- Screening
- Skin Cancer & Melanoma
- Surgery
- Thyroid Cancer